Syncona Limited Autolus announces pricing of public offering (8759V)
April 11 2019 - 2:09AM
UK Regulatory
TIDMSYNC
RNS Number : 8759V
Syncona Limited
11 April 2019
Syncona Limited
Autolus announces pricing of public offering
11 April 2019
Syncona Ltd, a leading healthcare company focused on founding,
building and funding global leaders in life science, notes that its
portfolio company, Autolus Therapeutics plc ("Autolus") today
announced the pricing of its previously announced underwritten
public offering in the United States of 4,200,000 American
Depositary Shares ("ADSs") representing 4,200,000 ordinary shares,
at a public offering price of $24 per ADS, for total gross proceeds
of approximately $100.8 million (GBP77.0million([1]) ). All ADSs
sold in the offering were offered by Autolus.
Syncona has agreed to invest $24 million (GBP18.3 million1) in
the offering. Following the offering, Syncona retains a stake of
30.4% in Autolus (amounting to 14,592,098 ordinary shares) which
was valued at GBP270.9 million at close of business on 10 April
2019.
Martin Murphy, Chief Executive Officer of Syncona Investment
Management Limited and Director of Autolus, said, "Syncona's
approach is to support our companies over the long-term as they
seek to deliver their products to patients. We are demonstrating
this today with our further investment in Autolus which is focused
on developing next generation programmed T cell therapies for the
treatment of cancer. We look forward to continuing to support the
company towards this goal."
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
The securities referred to in this announcement are to be
offered only by means of a prospectus. When available, copies of
the prospectus can be obtained from Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY
10282, or by telephone at +1 866 471 2526 or by email at
prospectus-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at +1 877 821 7388 or by email at
Prospectus_Department@Jefferies.com. For the avoidance of doubt,
such prospectus will not constitute a "prospectus" for the purposes
of Directive 2003/71/EC (and amendments thereto, including
Directive 2010/73/EU, to the extent implemented in each relevant EU
member state) and will not have been reviewed by any competent
authority in any EU member state.
A registration statement on Form F-1 (File No. 333-230767)
relating to the ADSs being sold in this offering was declared
effective by the U.S. Securities and Exchange Commission on 10
April 2019.
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay / Siobhan Weaver
Tel: +44 (0) 20 3981 7940
FTI Consulting
Brett Pollard / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of
investments of Syncona Ltd. These statements and forecasts involve
risk and uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements and forecasts. Nothing in this
announcement should be construed as a profit forecast.
About Syncona
Syncona is a leading FTSE250 healthcare company focused on
founding, building and funding global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital,
and are established leaders in gene and cell therapy. We focus on
delivering dramatic efficacy for patients in areas of high unmet
need.
About Autolus
Autolus is a biopharmaceutical company developing
next-generation programmed T cell therapies for the treatment of
cancer.
[1] At exchange rate on the 10 April 2019
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PFUEAKLFFEKNEEF
(END) Dow Jones Newswires
April 11, 2019 02:09 ET (06:09 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Sep 2023 to Sep 2024